Action NBY NOVABAY PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués NovaBay Pharmaceuticals, Inc.

Actions

NBY

US66987P4090

Marché Fermé - Nyse
Autres places de cotation
 22:00:00 20/06/2024 		Varia. 5j. Varia. 1 janv.
2,28 USD -0,87% Graphique intraday de NovaBay Pharmaceuticals, Inc. -11,28% -68,07%
09/05 NovaBay Pharmaceuticals, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
09/05 Transcript : NovaBay Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American
BU
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
BU
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms
BU
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
BU
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon
BU
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
AQ
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
BU
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales
BU
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
BU
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
BU
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results
BU
NovaBay Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K
PU
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
BU
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
AQ
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
BU
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
AQ
NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales
BU
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union through Sonoma's Extensive Distributor Network
AQ
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor Network
BU
NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NBY
  4. Actualités NovaBay Pharmaceuticals, Inc.
  5. Communiqués